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Background: Since 2001, long-term, low-dose azithromycin treatment has been used for CF patients chronically infected with Pseudomonas
aeruginosa in the Copenhagen CF centre. Our study investigates changes in incidence of colonization with Staphylococcus aureus, Streptococcus
pneumoniae,Haemophilus influenzae andMoraxella catarrhalis and changes in macrolide sensitivity in these microorganisms during azithromycin
treatment.
Methods: CF patients treated continuously with azithromycin for at least 3 months were included. Results of microbiological examination,
including phage typing results of S. aureus, obtained during treatment were compared to results obtained 2 years before treatment.
Results: 70 patients (median age 29.1 years) treated for a median of 4 years (range 0.7–5.1) were included. Before treatment, 44 patients had at
least one culture positive for S. aureus compared to 25 patients during treatment (pb0.01). Mean percentage of sputum samples with growth of
S. aureus decreased from 12.1% (range 0–82.6%) before treatment to 6.1% (range 0–93.2) during treatment (pb0.0006). Prevalence's of
H. influenzae and S. pneumoniae also decreased significantly. Fifteen of 214 isolates (7%) of S. aureus were macrolide resistant before treatment,
increasing to 95 of 181 isolates (52.5%) during treatment (pb0.001). Macrolide resistant strains were found in 3 of 44 S. aureus colonized
patients before treatment and in 11 of 25 patients at some time during treatment (pb0.03), all belonging to different phage types. First resistant S.
aureus isolate was isolated after a median treatment duration of 1.5 years (range 0.3–2.9). No MRSA were isolated. Only 1 macrolide resistant
isolate of M. catarrhalis was found during treatment. No macrolide resistance was found in H. influenzae or S. pneumoniae.
Conclusion: Long-term, low-dose treatment with azithromycin in CF patients leads to reduced prevalence of S. aureus, S. pneumoniae, and
H. influenzae, but increased macrolide resistance in S. aureus. Reduction in the prevalence of S. aureus will make increasing macrolide resistance
clinically insignificant in these patients.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Azithromycin; Cystic fibrosis; Macrolide resistance; Prevalence; Staphylococcus aureus☆ Preliminary data have been presented at the European Respiratory Society
Annual Congress, Stockholm, Sweden, September 15–19 2007, and at the 20th
Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, No-
vember 2–5, 2006, and were published in abstract form in Pediatric Pulmonology
2006, supplement 29, 346.
⁎ Corresponding author. Department of Pediatrics 5003, Rigshospitalet, Bleg-
damsvej 9, 2100 Copenhagen, Denmark. Tel.: + 45 3545 4760; fax: +45 3545
6717.
E-mail address: christine.hansen@rh.regionh.dk (C.R. Hansen).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.09.0011. Background
In Cystic Fibrosis (CF), chronic pulmonary infection caused
by Pseudomonas aeruginosa is the main complication leading
to increased morbidity and mortality. Diffuse pan-bronchiolitis,
a disease well described in Japanese patients, shares some si-
milarities with CF, including chronic airway infection caused by
P. aeruginosa. In the late 1980s a beneficial effect of long-term,
low-dose treatment with the macrolide erythromycin in these
patients was shown [1]. This led to the first studies on the effectd by Elsevier B.V. All rights reserved.
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To date, several studies in CF patients using long-term, low-dose
azithromycin have shown similar, positive effects on change in
lung function, number of exacerbations and nutrition expressed
as body mass index (BMI). Randomized, placebo controlled,
double blinded multi-centre studies and retrospective studies
of the effect of this treatment both in CF patients chronically
infected with P. aeruginosa and in CF patients without chronic
infections have agreed on the positive effect [2,4–10].
The mechanisms of this effect are not fully understood: azi-
thromycin can inhibit quorum sensing in P. aeruginosa, which
controls formation of several virulence factors [11–16], azithro-
mycin shows anti-inflammatory effects [17–21] and inhibits the
production of alginate [22].
Continuing this low-dose treatment for several years has
raised the concern of possible appearance of macrolide resistant
microorganisms. CF patients are characterized by infections
caused by Staphylococcus aureus, Haemophilus influenzae
and also by Streptococcus pneumoniae and Moraxella catar-
rhalis— microorganisms also found in healthy individuals. A
few studies have found an increase in macrolide resistance in
these microorganisms isolated from CF patients in long-term,
low-dose azithromycin treatment [23,24].
In the Copenhagen CF centre, azithromycin has been used as
a standard treatment since 2001 for patients chronically infected
by P. aeruginosa [25]. Treatment has been discontinued only at
time of lung transplantation or on the occurrence of side effects
such as tinnitus.
The present study was done to investigate if azithromycin
treatment leads to changes in the incidence of colonization with
S. aureus, H. influenzae, S. pneumoniae, andM catarrhalis and/
or changes in the occurrence in macrolide resistance in these
microorganisms.
2. Materials and methods
2.1. Study design
A descriptive, retrospective study.
2.2. Patients
All 297 CF patients followed in the Copenhagen CF centre
were evaluated for inclusion in the study. All patients are seen
every month in the out patient clinic, and at each visit a sputum
sample or a sample of lower respiratory tract secretions obtained
by endo-laryngeal suction is examined microbiologically [26].
All patients treated with low-dose azithromcyin continuously for
at least 3 months prior to November 1st 2005 were identified, and
all microbiological culture results obtained for a period of 2 years
prior to start of azithromcyin and during treatment were used for
the study.
2.3. Treatment
Long-term, low-dose azithromycin treatment is tried in all
patients with established chronic, Gram-negative pulmonaryinfections, and in patients with recurrent P. aeruginosa isolates
despite continuous inhaled antibiotic therapy. Treatment is dis-
continued if unacceptable side effects occur. Azithromycin dose
in patients N40 kg was 250 mg every day, in patients b40 kg
250mg every other day. Smaller children received half the normal
dose as syrup.
2.4. Microbiological results
Number of positive cultures and number of all samples for
microbiological investigation was counted in the pre-treatment
and treatment period, and positive cultures expressed as the
percentage of all sputum samples taken for microbiological in-
vestigation. Number of patients with at least 1 positive culture of
the individual microorganisms was counted in the pre-treatment
and treatment period.
Growth on 7.5% NaCl plates was used to detect growth of
Staphylococcus species. Final identification of S. aureus was
based on conventional phenotypic characters; a colistin-zone
diameter of b16 mm, the ability to clot plasma (coagulase
production test) and positive Staphaurex Latex Kit (Remel
Europe Ltd.). S. pneumoniae, H. influenzae and B. catarrhalis
were identified based on conventional phenotypic characteristics.
2.5. Susceptibility to antibiotics
Primary sensitivity testingwas done using disc-diffusion (Neo-
Sensitabs®, Rosco, Taastrup, Denmark) on blood-agar plates
(Statens Serum Institute, Copenhagen, Denmark). Resistance to
either of the macrolides tested (erythromycin and azithromycin
and/or clarithromycin) was evaluated.
Number of macrolide resistant strains for each microorgan-
ism was counted and compared to total number of positive
cultures for that specific microorganism, and number of patients
with at least 1 macrolide resistant strain was counted in the pre-
treatment and treatment period.
Bacteriological investigations include phage typing of all
S. aureus isolates at the Statens Serum Institute, Copenhagen, as
reported previously [27]. These results were used to investigate
if clonal spread of macrolide resistant S. aureus had occurred.
2.6. Statistics
Percentage of sputum samples with growth of individual mic-
roorganisms was compared using Student's paired t-test. Number
of patients harbouring specific microorganisms and number of
macrolide resistant strains were compared using chi-square test.
Level of significance: p b0.05.
3. Results
3.1. Patients
70 patients were included in the study. Median age at onset
of treatment was 29.1 years (range 1.5–53.2 years). Sixty-one
of treated patients had well-established chronic airway infection
caused by P. aeruginosa, 5 of treated patients were developing
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airway infections caused by A. xylosoxidans or B. multivorans.
Median duration of azithromycin treatment per November 1st
2005 was 4 years (range 0.7–5.1 years).
3.2. Microbiology
Microbiological results from 6298 sputum samples were
evaluated: 2240 samples taken in the 2 years prior to treatment,
median 30 samples/patient (range 9–54) and 4058 samples
taken during treatment, median 59 samples/patient (range 14–
142).
The number of patients with at least one culture positive for
S. aureus decreased from 44 of 70 patients (63%) in the pre-
treatment period to 25 of 70 patients (36%) in the treatment
period (pb0.01). The prevalence of S. aureus decreased from a
mean of 12.1% of samples (median 4, range 0–82.6) before
treatment to a mean of 6.1% (median 0, range 0–93.2) during
treatment (pb0.0006). Although the numbers were small, the
prevalence of H. influenzae decreased significantly from a mean
of 1.5% (median 0, range 0–16.7) before treatment to a mean of
0.2% (median 0, range 0–3.2) during treatment (pb0.003). The
prevalence of S. pneumoniae also decreased from a mean of 1%
(median 0, range 0–16.7) before treatment to a mean of 0.3%
(median 0, range 0–4.3) (pb0.05). The prevalence of M.
catarrhalis, and the number of patients with at least one culture
positive for H. influenzae, S. pneumoniae and M. catarrhalis
did not change (Table 1).
3.3. Macrolide resistance
Prior to treatment, three patients had at least one macrolide
resistant isolate of S. aureus. During treatment, this number
increased to 11 patients (pb0.03). Two patients harboured
resistant isolates before and during treatment, and one patient
with macrolide resistant S. aureus prior to treatment lost the
macrolide resistant strain during treatment. The 9 patients with
no resistant isolates prior to Azithromcyin treatment had been
treated for a median of 1.5 years (range 0.3–2.9) at the time of
first resistant isolate.
Prior to treatment, 15 of 214 isolates (7%) of S. aureus were
macrolide resistant. During treatment, this number increased to
95 of 181 isolates (52.5%) (pb0.001).
Phage typing showed that phage types found in CF patients
were the same phage types found in Denmark in general. De-
velopment of resistance occurred in phage types previouslyTable 1
Percentage of sputum samples with positive cultures of individual microorganisms a
Species Before treatment Du
Mean % Median % Range N Me
S. aureus 12.1 4.0 0–82.6 44 6.1
H. influenzae 1.5 0 0–16.7 15 0.2
S. pneumoniae 1 0 0–16.7 10 0.3
M. catarrhalis 0.6 0 0–20 5 0.1harboured by the patient. No spread of resistant clones was
found.
One macrolide resistant isolate of M. catarrhalis was found
during treatment. No macrolide resistant strains of H. influenzae
or S. pneumoniae were found at any time.
We found no methicillin resistant isolates of S. aureus
(MRSA) in the present study.
4. Discussion
Since the first results showing the positive effect of azi-
thromycin on progression on CF lung disease [2], long-term,
low-dose azithromycin has been used to treat an increasing
number of CF patients with chronic P. aeruginosa infection.
Lately the increase of macrolide resistance in S. aureus and
H. influenzae have been reported following this treatment regi-
men [23,24]. These reports inspired us to undertake the present
study, since azithromycin has been used for several years now in
the Copenhagen CF centre. Median treatment duration in the
study was 4 years.
6298 samples of lower airway secretion were included in the
study. The percentage of sputum cultures positive for S. aureus
was very low prior to treatment, median 4% (range 0–82.6%)
and decreased significantly (pb0.0006) during treatment, me-
dian 0% (range 0–93.2%). Treatment of S. aureus is very ag-
gressive in the Copenhagen CF centre [28] andb10% of patients
are chronically infected with S. aureus, explaining the very low
prevalence of S. aureus in sputum cultures. Number of patients
with at least one culture positive for S. aureus decreased
significantly from 44 before azithromycin treatment was started
to 25 after initiation of treatment.
It seems that long-term, low-dose azithromycin treatment
can provide some protection from S. aureus infections in CF,
but with increasing prevalence of macrolide resistance this may
change in the future. Saiman et al. [8] found significantly fewer
azithromycin treated patients with new S. aureus colonization
compared to patients receiving placebo; 2 of 84 patients in the
treatment group had new S. aureus colonization after 168 days,
while this was the case in 12 of 92 patients in the placebo group.
However, no difference was found when comparing proportion
of patients clearing S. aureus infection during the 168 days
of azithromycin treatment — in the azithromycin group, 18%
cleared the infection and in the placebo group, 12% of patients
cleared the S. aureus infection. The duration of S. aureus
infection, and whether these patients were chronically infected,
was not reported.nd number of patients with at least one positive culture of a microorganism (N)
ring treatment p-value
%
p-value
N
an % Median % Range N
0 0–93.2 25 b0.0006 b0.01
0 0–3.2 7 b0.003 n.s.
0 0–4.3 9 b0.05 n.s.
0 0–6.5 2 n.s. n.s.
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Rotterdam CF centre. Forty-one % of patients were chronically
infected with P. aeruginosa, but it was not reported how many
of these patients were treated with azithromycin. The observation
time was 5 years, and 41% of the patients followed in the centre
received azithromycin at some time. Indications for treatment
were progression of clinical symptoms and/or worsening of
pulmonary function, and poor response to conventional treatment.
Median duration of azithromycin treatment was 1.1 years (range
0.01–5). All isolates of S. aureus and H. influenzae from patients
receiving azithromycin treatment at the time of microbiological
examination were compared to isolates from patients not re-
ceiving azithromycin treatment at the time. Significantly fewer
isolates of S. aureuswere found in the azithromycin treated group.
A significantly larger proportion of macrolide resistant isolates of
S. aureus and H. influenzae were cultured, not only when
comparing samples from azithromycin treated patients to samples
from patients not receiving azithromycin at the time, but also
when comparing isolates from all CF patients to isolates from
non-CF patients. Furthermore, the proportion of S. aureus and
H. influenzae resistant to azithromycin increased during the ob-
servation time. It was not reported whether the included patients
were chronically infected with S. aureus. It was found that
P. aeruginosa carriage was associated with reduced isolation of
S. aureus and H. influenzae. The present study is not directly
comparable to the Rotterdam study by Phaff et al., since the
majority of our patients were chronically infected with P. aeru-
ginosa, the prevalence of S. aureus is very low and our patients
acted as their own controls: comparing sputum cultures prior to
azithromycin treatment to sputum cultures during azithromycin
treatment. In the study by Phaff et al. [23], azithromycin was
discontinued in the Rotterdam CF centre due to the increase in
macrolide resistance.
Tramper-Stranders et al. [24] studied CF patients chronically
infected with P. aeruginosa in the Utrecht CF centre. Clinical
and microbiological data for each year were compared from the
year prior to treatment start and during all years of treatment.
Median treatment duration was 3.5 years (range 0.9–7). A
slight, though not significant, decrease in S. aureus colonization
in azithromycin treated patients and significantly increasing
macrolide resistance in these patients were found. In this study,
around 50% of patients were colonized with S. aureus, which is
higher than in our study.
In the present stud, percentage of H. influenzae and S. pneu-
moniae in lower airway samples decreased significantly during
treatment (Table 1). Percentage of cultures positive for M. ca-
tarrhalis did not change during treatment. Number of patients
with at least one culture positive for any of the 3 microorgan-
isms did not change during azithromycin treatment. The number
of cultures positive for these 3 microorganisms was generally
very low.
We found a significant increase inmacrolide resistant S. aureus
strains from 7% to 52.5% of isolates (pb0.001). Furthermore, the
number of patients harbouring resistant strains increased sig-
nificantly from 3 to 11 of 70 patients (pb0.03).
Compared to the Danish population, phage types found in
CF patients did not differ from phage types found in general[29,30]. Occurrence of macrolide resistance is considerably
higher than the general macrolide resistance of almost 5%. In
individual patients we found development of resistance in phage
types harboured by the patient prior to treatment start. Some
patients continued to have intermittent occurrence of macrolide
sensitive strains after first appearance of resistance.
Tramper-Stranders et al. [31] investigated the possibility of
household transmission of macrolide resistant S. aureus from
CF patients to household contacts, and found that this could not
be proven. Possible transmission between CF patients was not
reported. In our study we found no sign of transmission between
patients when comparing phage types.
We found no increase in macrolide resistance inH. influenzae,
S. pneumoniae orM. catarrhalis.
No strains of methicillin resistant S. aureus (MRSA) were
found in our study, consistent with the low incidence of MRSA
in Denmark [28,32,33].
Because of our very aggressive treatment of S. aureus
colonization and infection and following a very low prevalence
of this microorganism in CF patients at the Copenhagen CF
centre [28], the occurrence of macrolide resistant S. aureus has
no impact on treatment of this infection, and long-term, low-
dose azithromycin treatment is continued.
The present study is a retrospective study. Further, preferably
prospective, studies are needed for effects of long-term azithro-
mycin on occurrence of macrolide resistance in household contacts
of treated patients, in CF patients not treated with azithromycin,
and of short-term azithromycin treatment in CF patients and other
patient groups.
4.1. Conclusion
Long-term, low-dose azithromycin treatment reduces the
prevalence of S. aureus, H. influenzae and S. pneumoniae in CF
patients, but leads to an increase in macrolide resistance in
S. aureus isolates from these patients. Treatments strategies
resulting in a reduction of prevalence of S. aureus in CF popu-
lations are important. Reduction in the prevalence of S. aureus
will make increasing macrolide resistance clinically insignif-
icant. The azithromycin treatment strategy in chronically in-
fected CF patients has been shown to be beneficial in this patient
population and should not be discontinued.
References
[1] Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A.
Long-term low-dose administration of erythromycin to patients with dif-
fuse panbronchiolitis. Respiration 1991;58(3–4):145–9.
[2] Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin
may improve lung function in children with cystic fibrosis. Lancet 1998
Feb 7;351(9100): 420.
[3] Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: east meets west.
Thorax 1994 Jun;49(6):531–2.
[4] Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term
effects of azithromycin in patients with cystic fibrosis: a double blind,
placebo controlled trial. Thorax 2006 Oct;61(10):895–902.
[5] Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin
in children with cystic fibrosis: a randomised, placebo-controlled crossover
trial. Lancet 2002 Sep 28;360(9338):978–84.
62 C.R. Hansen et al. / Journal of Cystic Fibrosis 8 (2009) 58–62[6] Hansen CR, Pressler T, Koch C, Høiby N. Long-term azitromycin treat-
ment of cystic fibrosis patients with chronic Pseudomonas aeruginosa
infection; an observational cohort study. J Cyst Fibros 2005 Mar;4(1):
35–40.
[7] Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function
and body mass index associated with long-term use of macrolide anti-
biotics. J Cyst Fibros 2003 Jun;2(2):69–71.
[8] Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL,
Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically
infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA 2003 Oct 1;290(13):1749–56.
[9] Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fi-
brosis. Cochrane Database Syst Rev 2004(2):CD002203.
[10] Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of
long term treatment with azithromycin on disease parameters in cystic
fibrosis: a randomised trial. Thorax 2002 Mar;57(3):212–6.
[11] Gillis RJ, Iglewski BH. Azithromycin retards Pseudomonas aeruginosa
biofilm formation. J Clin Microbiol 2004 Dec;42(12):5842–5.
[12] Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno
H, et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeru-
ginosa through interaction with the outer membrane. Antimicrob Agents
Chemother 2005 Apr;49(4):1377–80.
[13] Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas
aeruginosa virulence factors by subinhibitory concentrations of azithromycin
and other macrolide antibiotics. J Antimicrob Chemother 1993 May;31(5):
681–8.
[14] Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C.
Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.
Antimicrob Agents Chemother 2001 Jun;45(6):1930–3.
[15] Tateda K, Ishii Y,Matsumoto T, FuruyaN, NagashimaM,Matsunaga T, et al.
Direct evidence for antipseudomonal activity of macrolides: exposure-
dependent bactericidal activity and inhibition of protein synthesis by erythro-
mycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother
1996 Oct;40(10):2271–5.
[16] Hoffmann N, Lee B,HentzerM, Rasmussen TB, Song Z, JohansenHK, et al.
Azithromycin blocks quorum sensing and alginate polymer formation and
increases the sensitivity to serum and stationary-growth-phase killing of
Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection
in Cftr(−/−) mice. Antimicrob Agents Chemother 2007 Oct;51
(10):3677–87.
[17] Amsden GW. Anti-inflammatory effects of macrolides— an underappre-
ciated benefit in the treatment of community-acquired respiratory tract
infections and chronic inflammatory pulmonary conditions? J Antimicrob
Chemother 2005 Jan;55(1):10–21.
[18] Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al.
Azithromycin modulates neutrophil function and circulating inflammatory
mediators in healthy human subjects. Eur J Pharmacol 2002Aug 30;450(3):
277–89.[19] Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al.
Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther
2000 Jan;292(1):156–63.
[20] Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease.
Pediatr Pulmonol 2001 Jun;31(6):464–73.
[21] Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxi-
thromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998
Mar;41:47–50 Suppl B.
[22] Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic
possibilities of macrolides. Am J Med 1995 Dec 29;99(6A):26S–30S.
[23] Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Sta-
phylococcus aureus and Haemophilus species associated with long-term
azithromycin use in cystic fibrosis. J AntimicrobChemother 2006 Apr;57(4):
741–6.
[24] Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.
Maintenance azithromycin treatment in pediatric patients with cystic fibro-
sis: long-term outcomes related to macrolide resistance and pulmonary
function. Pediatr Infect Dis J 2007 Jan;26(1):8–12.
[25] Hansen CR, Pressler T, KochC, Høiby N. Long-term azithromycin treatment
of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection;
an observational cohort study. J Cyst Fibros 2005 Mar;4(1):35–40.
[26] Høiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Hodson M,
Geddes DM, editors. 2 ed. London: Arnold; 2000. p. 83–107.
[27] Hoff GE, Holby N. Staphylococcus aureus in cystic fibrosis: antibiotic
sensitivity and phage types during the latest decade. Investigation of the
occurrence of protein A and some other properties of recently isolated
strains in relation to the occurrence of precipitating antibodies. Acta Pathol
Microbiol Scand [B] 1975 Jun;83(3):219–25.
[28] Szaff M, Hoiby N. Antibiotic treatment of Staphylococcus aureus infection
in cystic fibrosis. Acta Paediatr Scand 1982 Sep;71(5):821–6.
[29] Larsen AR, Pallesen LV, Skov R. Annual Report on Staphylococcus aureus
Bacteraemia Cases 2004; 2005. http://www ssi dk/graphics/dk/overvagning/
sygdomsovervaagning/staph-grafer/rapport04/Annual04 pdf.
[30] Staphylococcus laboratory SSI. Phagetypes and resistance-patterns in Sta-
phylococcus aureus bacteraemia cases compared with all reported Staphy-
lococcus aureus cases; 1999. http://www ssi dk/graphics/dk/overvagning/
staph99-comparison pdf.
[31] Tramper-Stranders GA, van der Ent CK, Gerritsen SA, Fleer A, Kimpen JL,
Wolfs TF. Macrolide-resistant Staphylococcus aureus colonization in cystic
fibrosis patients: is there transmission to household contacts? J Antimicrob
Chemother 2007 Sep;60(3):665–8.
[32] Faria NA, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R, et al.
Epidemiology of emerging methicillin-resistant Staphylococcus aureus
(MRSA) in Denmark: a nationwide study in a country with low prevalence
of MRSA infection. J Clin Microbiol 2005 Apr;43(4):1836–42.
[33] Larsen AR, Bocher S, Stegger M, Goering R, Pallesen LV, Skov R.
Epidemiology of the European community-associated methicillin-resistant
Staphylococcus aureus clonal complex 80 type IV strains isolated in
Denmark from 1993 to 2004. J Clin Microbiol 2008 Jan;46(1):62–8.
